Loading market dashboard
Renalytix Plc
RNLXHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
The novel care model will integrate FDA-approved kidneyintelX.dkd™ and Carna Health's digital health platform to identify at-risk patients, halt disease progression, and slash healthcare costs, significantly benefiting US health systems and providers NEW YORK and BOSTON, May 12, 2026 /PRNewswire/ -- Renalytix PLC (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, and Carna Health, an AI-enabled digital health company revolutionizing chronic disease prevention, both leaders in improving outcomes in chronic kidney disease (CKD), today announced a landmark partnership designed to transform how health systems identify, stratify, and manage chronic kidney disease and its interconnected cardiovascular-kidney-metabolic (CKM) complications. By integrating Renalytix's FDA-approved kidneyintelX.dkd test, the gold standard in predicting progressive decline in kidney function in patients with type 2 diabetes and early-stage CKD, with Carna Health's AI-driven prevention and digital care management platform, health systems can benefit from moving beyond traditional detection to risk-guided, personalized care pathways that enable earlier, targeted interventions before patients reach catastrophic, high-cost clinical milestones.
Renalytix PLC (AIM:RENX, OTC:RNLXY, FRA:2O9) grew first-half revenue to US$1.6 million and trimmed its underlying EBITDA loss, but said full-year sales are now expected to come in at around US$4 million as healthcare-system integrations take longer to convert into revenue. The kidney disease diagnostics group said revenue for the six months to 31 December 2025 rose from US$1.3 million a year earlier, while underlying EBITDA loss narrowed to US$6.4 million from US$7.2 million and operating loss improved to US$7.1 million from US$7.5 million.
